Q-omics provides the consensus-scored CHRM4 profile across patient tissues and cancer cell-line models. CHRM4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHRM4 is differentially expressed in 12, with the highest sampling consensus in STAD. Additionally, CHRM4 RNA expression shows 17,246 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, STAD, and THYM as cancer lineages where CHRM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRM4 survival associations across molecular data types. CHRM4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRM4 RNA expression–survival associations across cancer types. High CHRM4 expression shows unfavorable associations in ACC, MESO and BLCA, but favorable associations in LGG, LUAD and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHRM4 RNA expression.
This table summarizes CHRM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for CHRM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRM4 shows lower tumor expression in STAD, COAD and LUAD and higher tumor expression in KIRP, HNSC and BRCA. The STAD box plot shows higher CHRM4 RNA expression in normal versus tumor tissue (log2 FC = −0.819, t-test p < 0.001).
This table shows molecular features associated with CHRM4 in patient tissues and cancer cell lines. In patient samples, CHRM4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
